Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4848-4854

  Govindan, Ramaswamy ^a   Crowley, John ^a   Schwartzberg, Lee ^a   Kennedy, Peter ^a   Williams, Charles ^a   Ekstrand, Bradley ^a   Sandler, Alan ^a   Jaunakais, Dinah ^a   Bolejack, Vanessa ^a   Ghalie, Richard ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEXAROTENE; ERLOTINIB; GEFITINIB; LEVOTHYROXINE; PLATINUM COMPLEX; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TETRALIN DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SIDE EFFECT; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; LUNG TUMOR; MICROCAPSULE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RASH; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; CAPSULES; CARCINOMA, NON-SMALL-CELL LUNG; EXANTHEMA; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION; SURVIVAL ANALYSIS; TETRAHYDRONAPHTHALENES;

EID: 33750609546     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.7404     Document Type: Article

References (42)

1. Weick JK, Crowley J, Natale RB, et al: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 9:1157-1162, 1991
2. Kelly K, Crowley J, Bunn P, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 19:3210-3218, 2001
3. Scagliotti GV, De Marinis D, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
4. Schiller JH, Harrington D, Sandler A, et al: Comparison of four chemotherapy regimens in advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
5. Giaccone G: Twenty-five years of treating advanced NSCLC: What have we achieved? Ann Oncol 15:iv81-iv83, 2004
6. Shepherd FA, Ramlau R, Mattson K, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
7. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
8. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
9. Massarelli E, Andre A, Liu JJ, et al: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:55-61, 2003
10. Edelman MJ: Second-line chemotherapy and beyond for non-small cell lung cancer. Clin Adv Hematol Oncol 2:373-378, 2004
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
12. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
13. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
14. Giaccone C, Herbst RS, Maegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784, 2004
15. Herbst RS, Giaccone C, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004
16. Kliewer SA, Umesono K, Mangelsdorf DJ, et a : Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signaling. Nature 355:446-449, 1992
17. Zhang XK, Hoffman B, Tran PBV, et al: Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 355:441-446, 1992
18. Keller H, Dreyer C, Medin J, et al: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A 90:2160-2164, 1993
19. Apfel R, Benbrook D, Lernhardt E, et al: A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 14:7025-7035, 1994
20. Forman BM, Goode E, Chen J, et al: Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687-693, 1995
21. Choi HS, Chung M, Tzameli I, et al: Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J Biol Chem 272:23565-23571, 1997
22. Rigas JR, Dragnev KH, Petty WJ, et al: A proof-of-principle trial of bexarotene in patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol 23:643s, 2005 (suppl; abstr 7093)
23. Xu XC, Sozzi G, Lee JS, et al: Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 89:624-629, 1997
24. Picard E, Seguin C, Monhoven N, et al: Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 91:1059-1066, 1999
25. Brabender J, Danenberg KD, Metzger R, et al: The role of retinoid X receptor messenger RNA expression in curatively resected non-small-cell lung cancer. Clin Cancer Res 8:438-443, 2002
26. Brabender J, Metzger R, Salonga D, et al: Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: Implications for tumor development and prognosis. Carcinogenesis 26:525-530, 2005
27. Simeone AM, Tari AM: How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61:1475-1484, 2004
28. Zhang C, Hazarika P, Ni X, et al: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Clin Cancer Res 8:1234-1240, 2002
29. Wu K, Kim HT, Rodriquez JL, et al: Suppression of mammary tumorigenesis in transgenic mice by the RXR- selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11:467-474, 2002
30. Miller VA, Benedetti FM, Rigas JR, et al: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15:790-795, 1997
31. Rizvi NA, Marshall JL, Dahut W, et al: Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5:1658-1664, 1999
32. Khuri FR, Rigas JR, Figlin RA, et al: Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 19:2626-2637, 2001
33. Edelman MJ, Smith R, Hausner P, et al: Phase II trial of the novel retinoid bexarotene and gemcitabine/carboplatin in advanced non-small cell lung cancer. J Clin Oncol 23:5774-5778, 2005
34. Rizvi N, Hawkins M, Eisenberg PD, et al: Placebo-controlled trial of bexarotene, a retinoid X receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clinical Lung Cancer 2:210-215, 2001
35. Blumenschein GR, Khuri F, Gatzemeier U, et al: SPIRIT II Lung Cancer Study Group: A randomized phase III trial comparing bexarotene/carboplatin/ paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 23:621s, 2005 (suppl; abstr LBA7001)
36. Jassem J, Zatloukal P, Ramlau R, et al: SPIRIT I Lung Cancer Study Group: A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 23:627s, 2005 (suppl; abstr LBA7024)
37. Govindan R, Crowley J, Schwartzberg L, et al: Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB/IV disease. J Clin Oncol 23:649s, 2005 (suppl; abstr 7116)
38. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
39. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol 1:245-250, 2000
40. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: Focus on bexarotene. Oncologist 10:22-33, 2005
41. Esteva JE, Glaspy J, Baidas S, et al: Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 21:999-1006, 2003
42. Dragnev KH, Petty WJ, Shah S, et al: Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23:8757-8764, 2005